Pilot Study Evaluating Ultra-High Dose Rate ConformalFLASH Proton Therapy for Reirradiation in Head and Neck Cancer Patients Not Eligible for Surgery
Led by IBA Proton Therapy, Inc. · Updated on 2026-09-18
10
Participants Needed
1
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the feasibility of ultra-high dose-rate conformal proton therapy ConformalFLASH for patients with head and neck cancer who need re-irradiation but cannot have surgery. This pilot study compares ConformalFLASH treatment planning and delivery to conventional Stereotactic Body Radiation Therapy SBRT, a standard re-irradiation approach. The study aims to explore if ultra-high dose rates can reduce normal tissue damage while maintaining tumor control.
Participants will receive ConformalFLASH irradiation using pencil-beam scanning proton therapy without chemotherapy. Treatment involves five fractions of 8 GyRBE each, delivered over approximately 1.5 to 2 weeks. The planning and delivery process follows SBRT workflows, focusing on dose rates of at least 40 GyRBE per second. This investigational treatment is designed for patients who have previously had significant radiation to the head and neck.
During the study, participants will undergo treatment delivery and monitoring for acute toxicities up to three months after starting treatment. Researchers will also evaluate treatment accuracy, late toxicities, tumor control at 3 months and 1 year, survival, and patient quality of life over up to 5 years. Participants provide informed consent and are followed closely to assess outcomes and safety throughout the study period.
CONDITIONS
Brief Title
A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck
Research Team
S
Sophie Le Bail
S
Sofie Gillis
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
ConformalFLASH proton reirradiation
Standard SBRT reirradiation
What it is
Ultrahigh‑dose‑rate proton stereotactic reirradiation (ConformalFLASH) delivered as 8 GyRBE × 5 fractions over about 1.5–2 weeks at ≥ 40 GyRBE/second, without chemotherapy
Conventional SBRT‑based reirradiation using multiple fractions of focused radiation to recurrent head and neck cancer in previously irradiated areas
Role in the trial
Single‑arm investigational treatment being evaluated for feasibility and safety
Current clinical practice outside the trial
Primary use
Reirradiation for recurrent head and neck carcinoma in previously irradiated field
Reirradiation for similar recurrent head and neck cancer scenario
How it is given or performed
Pencil‑beam scanning proton therapy at ultrahigh dose rate (≥ 40 GyRBE/s) given in five 8 GyRBE fractions over about 1.5–2 weeks
Stereotactic body radiation therapy delivered in multiple precise high‑dose fractions over a short course
Evidence status
Feasibility and acute toxicity are being evaluated; no efficacy or long‑term outcomes yet reported
SBRT reirradiation has growing evidence supporting tumor control and symptom management with similar survival compared to conventional approaches
Important risks
Under evaluation in trial; potential risks include acute and late radiation toxicity typical to reirradiation
SBRT reirradiation may cause similar toxicities including rare but serious events such as carotid artery rupture
Important limitations
Single‑arm pilot study with small sample size and no control arm; long‑term safety and efficacy unknown
Limited high‑level evidence; guidance is based on expert consensus rather than randomized trials
Patient‑relevant outcomes
Not yet established; outcomes like survival, quality of life, and control remain under study
SBRT reirradiation shows potential for local control and symptom benefit but high‑quality long‑term outcome data remain limited
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Patients must sign informed consent acknowledging the investigational nature and risks
Adults 18 years or older
Not eligible for or decline surgical resection
Histologically confirmed head and neck carcinoma
Prior receipt of at least 45 GyRBE radiotherapy to head and neck
ECOG Performance Status 0-2 or similar
Life expectancy over 12 weeks
Ability and willingness to follow study procedures and provide consent
You will not qualify if you...
Head and neck radiotherapy within the past 6 months
Surgical resection of current head and neck disease
More than 3 areas needing reirradiation
Disease larger than 6.5 cm in greatest dimension
Presence of distant metastases
Involvement of skin, carotid artery, or mandible
Concurrent chemotherapy during radiotherapy
Uncontrolled medical, psychiatric, or social issues limiting compliance
Enrollment in other investigational cancer therapy studies during radiotherapy
Pregnant or breastfeeding
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 1.5 to 2 weeks
Participants receive ConformalFLASH proton therapy in five sessions over 1.5 to 2 weeks.
5 treatment visits
Follow-up
Duration - Up to 5 years
Participants are monitored for acute side effects up to 3 months after treatment start, as well as for late toxicities and clinical outcomes up to 5 years.
Regular follow-up visits at specified intervals
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Evaluation of ALX2004 Antibody Drug Conjugate in Advanced or Metastatic Solid Tumors Including Lung, Head and Neck, Esophageal, and Colorectal Cancer
Developing an AI-Based Risk Prediction Model Integrating Clinical and Imaging Data for Head and Neck Cancerous Lesions
Personalized Physical Activity Intervention Using Motion Exergames to Manage Fatigue and Pain After Head and Neck Cancer Treatment
First-in-Human Study Evaluating EPI-326 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
Phase 2a Study to Evaluate Safety and Diagnostic Use of Pegsitacianine, an Imaging Agent for Detecting Head and Neck Cancer and Unknown Primary Cancer
Pilot Study Evaluating Ultra-High Dose Rate ConformalFLASH Proton Therapy for Reirradiation in Head and Neck Cancer Patients Not Eligible for Surgery
Phase II Study of Immune Maintenance Therapy with Toripalimab for Adults Aged 18 to 80 With Locally Advanced Head and Neck Squamous Cell Carcinoma After Neoadjuvant Immunotherapy and Chemotherapy
Phase 2 Study Comparing Cemiplimab Alone or With Fianlimab for Adults With HPV-Positive Head and Neck Cancer After Treatment
NECTINIUM-2 Evaluating Safety and Effectiveness of Nectin-4 Radiopharmaceutical 225AcAc-AKY-1189 in Previously Treated Advanced or Metastatic Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.